Castleark Management LLC Invests $8.08 Million in Bruker Corporation $BRKR

Castleark Management LLC bought a new position in shares of Bruker Corporation (NASDAQ:BRKR) in the second quarter, Holdings Channel.com reports. The institutional investor bought 134,270 shares of the medical research company’s stock, valued at approximately $8,080,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Orbis Allan Gray Ltd grew its stake in shares of Bruker by 5.4% during the 4th quarter. Orbis Allan Gray Ltd now owns 14,906,730 shares of the medical research company’s stock worth $702,256,000 after purchasing an additional 761,258 shares during the period. Pallas Capital Advisors LLC purchased a new stake in Bruker during the second quarter worth $570,746,000. State Street Corp boosted its holdings in Bruker by 2.5% during the fourth quarter. State Street Corp now owns 3,831,814 shares of the medical research company’s stock worth $180,700,000 after buying an additional 91,706 shares in the last quarter. AQR Capital Management LLC grew its position in Bruker by 125.3% during the second quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock valued at $137,065,000 after buying an additional 1,850,215 shares during the period. Finally, Sculptor Capital LP increased its holdings in Bruker by 9.0% in the first quarter. Sculptor Capital LP now owns 3,270,000 shares of the medical research company’s stock valued at $118,112,000 after buying an additional 270,000 shares in the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

Bruker Stock Down 0.2%

Shares of NASDAQ BRKR opened at $56.85 on Wednesday. The firm has a market cap of $8.66 billion, a price-to-earnings ratio of -81.21, a price-to-earnings-growth ratio of 1.74 and a beta of 1.28. The company’s 50-day simple moving average is $58.69 and its 200-day simple moving average is $47.71. The company has a quick ratio of 0.92, a current ratio of 1.85 and a debt-to-equity ratio of 0.76. Bruker Corporation has a 52-week low of $28.53 and a 52-week high of $65.30.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.11. The firm had revenue of $838.50 million during the quarter, compared to the consensus estimate of $853.57 million. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.32 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Equities analysts predict that Bruker Corporation will post 2.12 EPS for the current fiscal year.

Bruker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Monday, September 21st will be paid a $0.05 dividend. The ex-dividend date of this dividend is Monday, September 21st. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.4%. Bruker’s payout ratio is currently -28.57%.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on BRKR. Leerink Partners increased their target price on shares of Bruker from $60.00 to $70.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 7th. JPMorgan Chase & Co. lifted their price target on Bruker from $55.00 to $65.00 and gave the company an “overweight” rating in a research note on Monday, June 8th. UBS Group set a $60.00 price target on Bruker in a report on Wednesday, June 24th. TD Cowen reiterated a “hold” rating on shares of Bruker in a research report on Wednesday, July 15th. Finally, Guggenheim raised their price objective on Bruker from $50.00 to $70.00 and gave the company a “buy” rating in a report on Monday, June 29th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $56.64.

Bruker Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.